Research finds insufficient data transparency for FDA-cleared AI devices in Alzheimer’s imaging, raising bias and generalizability concerns.
Key Details
- 124 AI/ML-based devices for Alzheimer's disease and related dementias (ADRD) were FDA-authorized between January 2015 and December 2024.
- 291.7% (22/24) were cleared via the 510(k) pathway; 8.3% (2/24) through de novo classification.
- 3For 12 devices, there was no info on training or validation data in FDA summaries or peer-reviewed articles.
- 4Only 2 FDA summaries (8.3%) included external validation data; 10 peer-reviewed articles (41.7%) provided such data.
- 5Reporting of disease status, age, sex, race, and ethnicity was rare across most devices; demographic transparency was lacking.
- 6Most devices (21) were reviewed by radiology panels and primarily involved MRI and PET imaging.
Why It Matters
Transparent disclosure of training and validation data, especially demographic details, is vital for assessing bias and clinical accuracy in AI-based imaging devices. Without sufficient data transparency, there is uncertainty about the generalizability and safety of these AI tools in real-world, diverse patient populations.
Source
AuntMinnie
Related News
•Radiology Business
Hybrid AI Approach Cuts Mammography Workload by 38%
A Dutch research team demonstrated that a 'hybrid' AI strategy can reduce radiologist workload in mammography screening by nearly 40% without affecting performance.
•AuntMinnie
Habitat AI Model Improves Risk Stratification of Lung Nodules on LDCT
A 'habitat' AI model outperforms standard 2D approaches in stratifying lung adenocarcinoma risk in subsolid nodules on low-dose CT scans.
•AuntMinnie
AI Model Uses Chest CT to Diagnose and Grade COPD Severity
A machine learning model based on chest CT images accurately diagnoses and grades the severity of COPD.